Evaluation agreement with Hemakim regarding the Turkish market transferred into distribution agreement

Hemcheck Sweden AB and Hemakim Tibbi Ürünler San.Ve Tic. A.S (”Hemakim”) has agreed to continue the collaboration into a distribution agreement regarding the Turkish market valid until the end of May 2023. The market research and tests performed during the evaluation period have all turned out well.

-We are very glad for the positive market feedback. The Turkish market is large with good potential for our products, and we look forward to continue working with Hemakim, says Joen Averstad, CEO of Hemcheck.

-We continue to be very positive about the potential of Hemcheck’s products in the Turkish market after the evaluation period, and we look forward to continuing the collaboration, says Aziz Eroglu, CEO of Hemakim. 

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemakim

Hemakim is a family-owned Turkish company group founded in 1983. The Group consists of several legal entities focusing on a wide number of fields such as in-vivo and in-vitro diagnostics in hospitals, immunohematology, microbiology, etc. Hemakim has its head office in Istanbul and has several regional offices and sub-dealers throughout Turkey. The group turnover is ca 50 MUSD. Hemakim is a partner to several large companies such as Thermo Scientific.

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.